<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84314</article-id><article-id pub-id-type="doi">10.7554/eLife.84314</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Complementary CRISPR screen highlights the contrasting role of membrane-bound and soluble ICAM-1 in regulating antigen specific tumor cell killing by cytotoxic T cells</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-331674"><name><surname>Herzfeldt</surname><given-names>Ann-Kathrin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-298360"><name><surname>Gamez</surname><given-names>Marta Puig</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-298361"><name><surname>Martin</surname><given-names>Eva</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-298365"><name><surname>Boryn</surname><given-names>Lukasz Miloslaw</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-8091-1071</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" id="author-298366"><name><surname>Baskaran</surname><given-names>Praveen</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2275-3516</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" id="author-298363"><name><surname>Huber</surname><given-names>Heinrich J</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4454-2971</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf7"/></contrib><contrib contrib-type="author" id="author-298770"><name><surname>Schuler</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf8"/></contrib><contrib contrib-type="author" corresp="yes" id="author-298347"><name><surname>Park</surname><given-names>John E</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5674-6026</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf9"/></contrib><contrib contrib-type="author" id="author-298359"><name><surname>Swee</surname><given-names>Kim Lee</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf10"/></contrib><aff id="aff1"><institution content-type="dept">Department of Cancer Immunology and Immune Modulation</institution>, <institution>Boehringer Ingelheim</institution>, <addr-line><named-content content-type="city">Biberach an der Riss</named-content></addr-line>, <country>Germany</country></aff><aff id="aff2"><institution content-type="dept">Department of Drug Discovery Sciences</institution>, <institution>Boehringer Ingelheim</institution>, <addr-line><named-content content-type="city">Biberach an der Riss</named-content></addr-line>, <country>Germany</country></aff><aff id="aff3"><institution>Ardigen SA</institution>, <addr-line><named-content content-type="city">Kraków</named-content></addr-line>, <country>Poland</country></aff><aff id="aff4"><institution content-type="dept">Department of Global Computational Biology and Digital Sciences</institution>, <institution>Boehringer Ingelheim</institution>, <addr-line><named-content content-type="city">Biberach an der Riss</named-content></addr-line>, <country>Germany</country></aff><aff id="aff5"><institution content-type="dept">Drug Discovery Sciences</institution>, <institution>Boehringer Ingelheim</institution>, <addr-line><named-content content-type="city">Biberach an der Riss</named-content></addr-line>, <country>Germany</country></aff><aff id="aff6"><institution content-type="dept">Dept of Drug Discovery Services</institution>, <institution>Boehringer Ingelheim</institution>, <addr-line><named-content content-type="city">Biberach an der Riss</named-content></addr-line>, <country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-221774"><name><surname>Altman</surname><given-names>Brian</given-names></name><role>Reviewing editor</role><aff/></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>john.park@boehringer-ingelheim.com</email> (JP);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>09</month><year>2023</year></pub-date><volume>12</volume><elocation-id>e84314</elocation-id><history><date date-type="received"><day>19</day><month>10</month><year>2022</year></date><date date-type="accepted"><day>20</day><month>09</month><year>2023</year></date></history><permissions><copyright-statement>© 2023, Herzfeldt et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Herzfeldt et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84314-v1.pdf"/><abstract><p>Cytotoxic CD8+ T lymphocytes (CTLs) are key players of adaptive anti-tumor immunity based on their ability to specifically recognize and destroy tumor cells. Many cancer immunotherapies rely on unleashing CTL function. However, tumors can evade killing through strategies which are not yet fully elucidated. To provide deeper insight into tumor evasion mechanisms in an antigen-dependent manner, we established a human co-culture system composed of tumor and primary immune cells. Using this system, we systematically investigated intrinsic regulators of tumor resistance by conducting a complementary CRISPR screen approach. By harnessing CRISPR activation (CRISPRa) and CRISPR knockout (KO) technology in parallel, we investigated gene gain-of-function as well as loss-of-function across genes with annotated function in a colon carcinoma cell line. CRISPRa and CRISPR KO screens uncovered 187 and 704 hits respectively, with 60 gene hits overlapping between both. These data confirmed the role of interferon‑γ (IFN-γ), tumor necrosis factor α (TNF-α) and autophagy pathways and uncovered novel genes implicated in tumor resistance to killing. Notably, we discovered that <italic>ILKAP</italic> encoding the integrin-linked kinase-associated serine/threonine phosphatase 2C, a gene previously unknown to play a role in antigen specific CTL-mediated killing, mediate tumor resistance independently from regulating antigen presentation, IFN-γ or TNF-α responsiveness. Moreover, our work describes the contrasting role of soluble and membrane-bound ICAM-1 in regulating tumor cell killing. The deficiency of membrane-bound ICAM-1 (mICAM-1) or the overexpression of soluble ICAM-1 (sICAM-1) induced resistance to CTL killing, whereas PD-L1 overexpression had no impact. These results highlight the essential role of ICAM-1 at the immunological synapse between tumor and CTL and the antagonist function of sICAM-1.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100008349</institution-id><institution>Boehringer Ingelheim</institution></institution-wrap></funding-source><award-id>none</award-id><principal-award-recipient><name><surname>Herzfeldt</surname><given-names>Ann-Kathrin</given-names></name><name><surname>Gamez</surname><given-names>Marta Puig</given-names></name><name><surname>Martin</surname><given-names>Eva</given-names></name><name><surname>Boryn</surname><given-names>Lukasz Miloslaw</given-names></name><name><surname>Baskaran</surname><given-names>Praveen</given-names></name><name><surname>Huber</surname><given-names>Heinrich J</given-names></name><name><surname>Schuler</surname><given-names>Michael</given-names></name><name><surname>Park</surname><given-names>John E</given-names></name><name><surname>Swee</surname><given-names>Kim Lee</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Ann-Kathrin Herzfeldt, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..</p></fn><fn fn-type="conflict" id="conf3"><p>Marta Puig Gamez, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..</p></fn><fn fn-type="conflict" id="conf4"><p>Eva Martin, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..</p></fn><fn fn-type="conflict" id="conf5"><p>Lukasz Miloslaw Boryn, was an Ardigen S.A. employee. The funder provided support in the form of salaries for the authors..</p></fn><fn fn-type="conflict" id="conf6"><p>Praveen Baskaran, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..</p></fn><fn fn-type="conflict" id="conf7"><p>Heinrich J Huber, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..</p></fn><fn fn-type="conflict" id="conf8"><p>Michael Schuler, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..</p></fn><fn fn-type="conflict" id="conf9"><p>John E Park, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..</p></fn><fn fn-type="conflict" id="conf10"><p>Kim Lee Swee, was an employee at this time of Boehringer Ingelheim Pharma GmbH Co. KG. The author has noother relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed..</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analyzed are included in the manuscript. Source data files are provided for figure 2 and figure 3</p></sec><supplementary-material><ext-link xlink:href="elife-84314-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>